Your browser is no longer supported. Please, upgrade your browser.
DBTX [NASD]
Decibel Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.81 Insider Own9.30% Shs Outstand25.09M Perf Week-7.22%
Market Cap264.45M Forward P/E- EPS next Y-0.90 Insider Trans180.35% Shs Float11.11M Perf Month-30.89%
Income-43.70M PEG- EPS next Q-0.54 Inst Own30.82% Short Float3.17% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.23 Perf Half Y-
Book/sh- P/B- EPS next Y47.70% ROA- Target Price- Perf Year-
Cash/sh2.16 P/C4.87 EPS next 5Y- ROE- 52W Range10.41 - 24.39 Perf YTD-41.54%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.46% Beta-
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low2.02% ATR1.08
Employees37 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)29.90 Volatility5.56% 8.07%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.03 Prev Close10.54
ShortableYes LT Debt/Eq- EarningsMar 29 AMC Payout- Avg Volume286.91K Price10.62
Recom1.50 SMA20-16.34% SMA50-29.11% SMA200-29.11% Volume7,855 Change0.76%
Mar-09-21Initiated SVB Leerink Outperform $26
Mar-09-21Initiated Citigroup Buy $29
Mar-09-21Initiated BMO Capital Markets Outperform $30
Mar-09-21Initiated Barclays Overweight $30
Apr-08-21 08:00AM  
Mar-29-21 04:05PM  
Mar-22-21 08:00AM  
Mar-05-21 08:46PM  
Mar-04-21 08:00AM  
Feb-24-21 07:00AM  
Feb-19-21 07:00AM  
Feb-12-21 05:05PM  
Feb-11-21 09:51PM  
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLCDirectorFeb 17Buy18.00150,0002,700,0001,183,663Feb 19 04:50 PM
ORBIMED ADVISORS LLCDirectorFeb 17Buy18.001,666,66629,999,9883,843,206Feb 19 07:09 PM
Foy MatthewDirectorFeb 17Buy18.00150,0002,700,0001,183,663Feb 19 06:59 PM
Casdin Partners Master Fund, L10% OwnerFeb 17Buy18.00575,00010,350,0001,121,421Feb 19 06:56 PM
Thompson Peter A.DirectorFeb 17Buy18.001,666,66629,999,9883,843,206Feb 19 06:50 PM